Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Standard
Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. / Rassaf, Tienush; Totzeck, Matthias; Backs, Johannes; Bokemeyer, Carsten; Hallek, Michael; Hilfiker-Kleiner, Denise; Hochhaus, Andreas; Lüftner, Diana; Müller, Oliver J; Neudorf, Ulrich; Pfister, Roman; von Haehling, Stephan; Lehmann, Lorenz H; Bauersachs, Johann; Committee for Clinical Cardiovascular Medicine of the German Cardiac Society.
In: CLIN RES CARDIOL, Vol. 109, No. 10, 10.2020, p. 1197-1222.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
AU - Rassaf, Tienush
AU - Totzeck, Matthias
AU - Backs, Johannes
AU - Bokemeyer, Carsten
AU - Hallek, Michael
AU - Hilfiker-Kleiner, Denise
AU - Hochhaus, Andreas
AU - Lüftner, Diana
AU - Müller, Oliver J
AU - Neudorf, Ulrich
AU - Pfister, Roman
AU - von Haehling, Stephan
AU - Lehmann, Lorenz H
AU - Bauersachs, Johann
AU - Committee for Clinical Cardiovascular Medicine of the German Cardiac Society
PY - 2020/10
Y1 - 2020/10
N2 - The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
AB - The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
U2 - 10.1007/s00392-020-01636-7
DO - 10.1007/s00392-020-01636-7
M3 - SCORING: Review article
C2 - 32405737
VL - 109
SP - 1197
EP - 1222
JO - CLIN RES CARDIOL
JF - CLIN RES CARDIOL
SN - 1861-0684
IS - 10
ER -